Toxoplasma gondii is the etiologic agent of toxoplasmosis, a disease which can lead to morbidity and mortality of the fetus and immunocompromised individuals. Due to the limited effectiveness or side effects of existing drugs, the search for better drug candidates is still ongoing. In this study, we performed structure-based screening of potential dual-targets inhibitors of active sites of T. gondii drug targets such as uracil phosphoribosyltransferase (UPRTase) and adenosine kinase (AK). First screening of virtual compounds from the National Cancer Institute (NCI) was performed via molecular docking. Subsequently, the hit compounds were tested in-vitro for anti-T. gondii effect using cell viability assay with Vero cells as host to determine cytotoxicity effects and drug selectivities. Clindamycin, as positive control, showed a selectivity index (SI) of 10.9, thus compounds with SI > 10.9 specifically target T. gondii proliferation with no significant effect on the host cells. Good anti-T. gondii effects were observed with NSC77468 (7-ethoxy-4-methyl-6,7-dihydro-5H -thiopyrano[2,3-d ] pyrimidin-2-amine) which showed SI values of 25. This study showed that in-silico selection can serve as an effective way to discover potentially potent and selective compounds against T. gondii.
Introduction
The parasite Toxoplasma gondii is an obligate intracellular protozoan that can infect all 2 warm-blooded animals including human. It infects ~30% of the human population 3 worldwide, and the prevalence is up to 90% in some European populations [1, 2] . In 4 Malaysia, chronic Toxoplasma infection was reported to vary from 10% to 50% [3] . In 5 healthy immunocompetent adults, most infections are asymptomatic, but may cause 6 lymphadenopathy and self-limiting flu-like symptoms. However, infection in 7 immunocompromised patients such as those with AIDS can lead to fatal encephalitis. 8 Furthermore, infection in seronegative pregnant women may lead to fetal infection that 9 result in stillbirth, ocular diseases and mental retardations [1, 4, 5] . 10 The most effective treatment for T. gondii infection is the synergistic combination of 11 pyrimethamine and sulphonamides, especially sulphadiazine. Sulphonamides inhibit 12 dihydrofolic acid synthetase while pyrimethamine inhibits dihydrofolate reductase, key 13 enzymes in the synthesis of purines [1] . Although the treatment is quite effective, it has 14 adverse effects especially in immunocompromised patients, such as haematological 15 toxicity caused by pyrimethamine; and cutaneous rash, leukopenia and 16 thrombocytopenia caused by the sulphonamide. The problems are compounded with 17 the fact that the drug has no efficacy against tissue cysts, thus may encourage the 18 appearance of resistant strains leading to the chance of recurrence after 19 treatment [1, 4, 5] . Other drugs being used for toxoplasmosis include clindamycin, 20 atovaquone and spiramycin [6] . Clindamycin is reported to be effective, but may cause 21 ulcerative colitis [7] . Spiramycin has lesser anti-T. gondii effects compared to 22 sulfadiazine and pyrimethamine; and it produces high tissue concentrations, 23 particularly in the placenta, but without crossing the placental barrier. Thus, the 24 development of new alternative drugs for the treatment of T. gondii infection is still 25 needed to address the above limitations. 26 This study used two reported key targets of T. gondii namely uracil 27 phosphoribosyltransferase ( UPRTase) and adenosine kinase (AK). The pyrimidine and 28 purine salvage pathways of T. gondii are good targets as these pathways are highly 29 dissimilar between the parasite and host. In T. gondii, the parasite synthesizes 30 pyrimidine nucleotide de novo and UPRTase is the only operative enzyme that salvages 31 pre-formed pyrimidines to the nucleotide level [2] . Meanwhile, targeting AK is 32 important because T. gondii needs to recover purine from the adenosine kinase since 33 the parasite is unable to synthesize purine [8] . It is therefore interesting to attain a 34 single compound which may be able to inhibit these two targets at once and potentially 35 serve as a good lead for further downstream investigations. 36 In this study, virtual screening of anti-T. gondii was used to screen for potential 37 drug candidates that have good complementarity in terms of shape and physico 38 -chemical properties with the selected drug targets. The National Cancer Institute 39 (NCI), USA database was used to virtually screen for anti-T. gondii. Subsequently pure 40 compounds of the in-silico hits were then obtained from the NCI for in vitro validation. 41 The selected pure compounds from the NCI database were tested using cell viability 42 assay with Vero cells as host to determine cytotoxicity effects and drug selectivity.
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Methods
44
Molecular docking 45 The protein-ligand docking using Autodock 3.05 for virtual screening workflow can 46 be divided into three steps: the preparation of receptors and ligands structures, docking, 47 and scoring [9] . The receptor targets selected were Uracil Phosphoribosyltransferase ( 48 UPRTase, PDB ID: 1UPF) and Adenosine Kinase (AK, 1LIJ) of T. gondii. In the 49 3/21 receptor structure's file preparation, the bound ligand and water molecules were 50 removed from the crystal structure. Polar hydrogens were added followed by adding 51 Kollman charges to the receptor's amino acid and the partial charges were computed. 52 The charged proteins were then solvated using the AutoDock3.0 " addsol " module and 53 atom types were assigned for the receptor using the AutoDockTools [10] . 54 In compound's library files, the files were downloaded from NCI that have hydrogen 55 atoms added to each compound, and subsequently converted from sdf format to mol2 56 format using OpenBabel [11] . The mol2 file, were separated into individual files and 57 renamed and converted to the AutoDock pdbq format to specify the rotatable bonds for 58 the docking conformational searches. The Gasteiger charges and maximum number of 59 rotatable bonds were applied to all the ligands. The grid parameter file was set-up 60 using AutoDockTools to constrain the search area. The parameters from the gpf file 61 were taken by AutoGrid and the grid maps were generated for use with AutoDock. Virtual screening 76 Prior to the screening, the 1855 of NCI compounds were filtered according the 77 druglikeness property Lipinski's rule of 5 [13] using Accelrys Discovery Studio Client 78 2.5 [14] and were minimized by MM+ force field using Hyperchem 7.0 [15] . Then, the 79 compounds from NCI databases were screened using the molecular docking method as 80 described above and evaluated their binding to the receptor targets. Compounds scored 81 favourably in term of the free energy of binding, the best ligand conformations and 82 interaction with the binding site's residues were chosen as hit compounds that may 83 potentially act as anti-T. gondii agents. 106 Vero cells were harvested by trypsinization when it reached 80-90% confluence and 107 centrifuged at 1000 x g for 5 mins (Eppendorf Centrifuge 5804R, Germany). The clean 108 Vero cell pellet was resuspended thoroughly with growth medium (GM) which 109 comprised Dulbecco's Modified Eagle medium [ DMEM] (Gibco, USA) containing 0.5% 110 penicillin-streptomycin (PS) and 5% fetal bovine serum (FBS). The number of cells was 111 counted with a hemocytometer under inverted light microscope, using the trypan blue 112 dye-exclusion method.
Counting of cells
113
Counting of parasites 114 T. gondii was freshly harvested from mice peritoneal fluid and collected in a tube. 115 The tube was centrifuged at 200 x g for 10 mins. The resulting supernatant which 116 contained more than 90% pure tachyzoites was collected; while the pellet which 117 contained mouse macrophage cells was discarded. The supernatant was centrifuged 118 again at 1000 x g for 10 mins to pellet the tachyzoites. The clean T. gondii pellet was 119 resuspended thoroughly with wash medium (WM) which comprised DMEM with 0.5% 120 PS and without FBS; and the number of viable T. gondii was counted as above. in triplicates and incubated for 24 hours [16] [17] [18] . 134 After treatment for 24 hours, the anti-T. gondii activity was examined using 135 MTS-PMS assay. MTS solution was prepared (2 mg/ml) by dissolving the powder in 136 PBS. Exposure to light was avoided during the preparation. PMS (0.92 mg/ml) was 137 similarly prepared in PBS and both solutions were stored at -20 0 C. A volume of 20 µl 138 of MTS solution was added into each well and the cells were incubated for one hour in a 139 CO 2 incubator [19, 20] . The absorbance (abs) was then measured at 490 nm using a 140 microplate reader (Thermo Scientific Multiskan ® Spectrum, USA). The percentage of 141 cell viability was calculated using the following formula [21, 22] . (Fig 1) . 176 Whilst, the docking of 2,7-iodotubercidin into AK (PDB ID: 1LIJ) also showed low 177 RMSD (0.51 Å) with the free energy of binding of -10.99 kcal/mol and predicted 178 inhibition constant, K i of 8.87 nM (Fig 2) . 179 The RSMD values obtained from this study were all below 1 Å with favourable free 180 energy of binding, thus these docking parameters could be used for subsequent dockings 181 (virtual screening). The best conformations and orientation of known inhibitors were 182 generated using Lamarckian genetic algorithm in AutoDock 3.0.5 while keeping the 183 enzyme structure rigid. ) and significant number of hydrophobic interactions (Fig 5) with both the target 208 enzymes i.e. UPRTase and AK. NSC77468 also was found to have the best aromatic 209 interaction bound to UPRTase and AK (Fig 6) . By inhibiting the parasite with 210 multi-target inhibitors, the complementarities binding in getting the best interactions 211 were also enhanced. Based on the analysis of the binding site interaction among the 212 NCI compounds, NSC77468 was found as the most ideal candidate for anti-T. gondii 213 compound among the eight top NCI compounds based on lowest free energy of binding, 214 the best ligand conformations, and good intermolecular interactions with the targets. 220 Based on the structure-activity relationship for the binding of ligands to UPRTase, 221 of the eight NCI compounds only NSC77468 and NSC343344 can be considered as uracil 222 analogue or pyrimidine analogue. The latter compound can be considered to be uracil 223 analogues in which endocyclic imine or methylene group are replaced with endocyclic 224 methylene or imine groups [25] . Table 2 increase the level of ionization of this compound relative to the uracil [25] . The 231 ionization occurs predominantly through the loss of N3 proton rather than the N1 232 proton [25] . Based on the binding of the NCI compounds at the binding site of AK, 233 only NSC77468 showed hydrogen bond interaction with the substrate; a 234 nonhydrolysable adenosine triphosphate analog (ACP) near Arg136. Guanidinium 235 group at the side chain of Arg136 has a function to activate and stabilize the phos phate 236 during catalysis (Fig 7) . Therefore, based on this structure-activity relationship, 237 NSC77468 could be developed into a lead compound which might provide better 238 activity than 5-fluorouracil. NSC77468 showed the highest SI (25) in the present study, demonstrating the 281 effectiveness of the compound against T. gondii while being safe to mammalian cells. 282 To the best of our knowledge, this is the first report on the good activity of NSC77468 283 against T. gondii. This compound is relatively rigid, with two rotatable bonds, and has 284 a tendency to be planar, with less chiral centers, and contain pharmacologically 285 desirable features such as no obvious leaving groups, no weakly bonded heteroatoms, no 286 organometallics and no polycyclic aromatic hydrocarbons.
Structure-activity relationship
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Conclusions 288
This study demonstrated that the approach to drug discovery by initially using 289 computer based in-silico screening followed by laboratory-based bio-assay can lead to 
